GB2394660A — Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide

USPTO Abstract

Stable pharmaceutical compositions comprising an ACE inhibitor (which are otherwise susceptible to degradation due to cyclisation, hydrolysis and oxidation) are provided. This is achieved by providing compositions substantially free of any acidic excipients having a large specific surface area, especially substantially free of colloidal silicon dioxide. The composition also comprises one or more excipients, which are preferably compatible with the ACE inhibitor. The ACE inhibitor is preferably perindopril or ramipril. The composition may be used as a medicament for the treatment or prevention of a cardiovascular disorder, hypertension, coronary heart disease or a cerebrovascular disease. The composition may further comprise a b -blocker, a diuretic, a calcium-channel blocker, a vasodilator anti- hypertensive drug, or an angiotensin II receptor antagonist.